Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Jun;11(6):555–559. doi: 10.1111/j.1365-2125.1981.tb01170.x

Comparison of four different beta-adrenoceptor blocking drugs on lymphocyte isoprenaline-stimulated cyclic AMP production.

D R Lima, S Kilfeather, A Hedges, P Turner
PMCID: PMC1402205  PMID: 6115666

Abstract

1 The influence of acebutolol, atenolol, pindolol and timolol on human lymphocyte cyclic AMP (cAMP) and its stimulation by isoprenaline in vitro has been studied. 2 Acebutolol and atenolol (10(-8)-10(-6)M) had no significant influence on lymphocyte cAMP levels or on isoprenaline-stimulated increase in cAMP. 3 Pindolol and timolol significantly antagonised the effect of isoprenaline, and pA2 values were calculated to be 8.12 and 8.04 respectively. This suggests that beta 2-adrenoceptors are involved in this phenomenon. 4 Only pindolol produced a significant increase in lymphocyte cAMP, which is consistent with its partial agonist activity.

Full text

PDF
555

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coleman A. J., Somerville A. R. The selective action of beta-adrenoceptor blocking drugs and the nature of beta1 and beta2 adrenoceptors. Br J Pharmacol. 1977 Jan;59(1):83–93. doi: 10.1111/j.1476-5381.1977.tb06980.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Conolly M. E., Greenacre J. K. The beta-adrenoceptor of the human lymphocyte and human lung parenchyma. Br J Pharmacol. 1977 Jan;59(1):17–23. doi: 10.1111/j.1476-5381.1977.tb06971.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davis C., Conolly M. E., Greenacre J. K. Beta-adrenoceptors in human lung, bronchus and lymphocytes. Br J Clin Pharmacol. 1980 Nov;10(5):425–432. doi: 10.1111/j.1365-2125.1980.tb01783.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hall R. A., Robson R. D., Share N. N. Timolol maleate, a new beta-adrenergic receptor blocking agent. Arch Int Pharmacodyn Ther. 1975 Feb;213(2):251–263. [PubMed] [Google Scholar]
  5. McDevitt D. G. The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol. 1977 Aug;4(4):413–425. doi: 10.1111/j.1365-2125.1977.tb00756.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Moore G. E., O'Donnell S. R. A potent beta-adrenoreceptor blocking drug: 4-(2-hydroxy-3-isopropylaminopropoxy)indole. J Pharm Pharmacol. 1970 Mar;22(3):180–188. doi: 10.1111/j.2042-7158.1970.tb08494.x. [DOI] [PubMed] [Google Scholar]
  7. Prichard B. N. The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol. 1978 May;5(5):379–399. doi: 10.1111/j.1365-2125.1978.tb01644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Steiner A. L., Parker C. W., Kipnis D. M. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem. 1972 Feb 25;247(4):1106–1113. [PubMed] [Google Scholar]
  9. Ulrych M., Franciosa J., Conway J. Comparison of a new beta adrenergic blocker (MK 950) and propranolol in man. Clin Pharmacol Ther. 1972 Mar-Apr;13(2):232–238. doi: 10.1002/cpt1972132232. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES